company background image
FRE logo

Fresenius SE KGaA XTRA:FRE Stock Report

Last Price

€39.71

Market Cap

€22.4b

7D

-0.7%

1Y

57.6%

Updated

03 Apr, 2025

Data

Company Financials +

Fresenius SE & Co. KGaA

XTRA:FRE Stock Report

Market Cap: €22.4b

FRE Stock Overview

A health care company, provides products and services for chronically ill patients. More details

FRE fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance1/6
Financial Health4/6
Dividends4/6

Rewards

Trading at 58.8% below our estimate of its fair value

Earnings are forecast to grow 15.17% per year

Risk Analysis

Has a high level of debt

Unstable dividend track record


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

FRE logo
Fresenius SE KGaA
AN
AnalystConsensusTarget
Consensus Narrative from 15 Analysts

I Expect New Biopharma Products And The Ivenix Pump Will Streamline Future Operations

Key Takeaways Strategic focus on core businesses and asset divestment is set to enhance earnings and operational transparency. Innovations in Biopharma and MedTech will drive growth and improve margins, with new products boosting future revenue and stability.
View narrative
€46.53
FV
14.7% undervalued intrinsic discount
4.57%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
23users have followed this narrative
1 day ago author updated this narrative
FRE logo
Fresenius SE KGaA
TO
Tokyo
Community Contributor

First comes the pain, then the money.

My main narrative for FRE: What former CEO Mark Schneider blow up to an inefficient giant, will now be cut down by actual CEO Michael Sen and trimmed on efficiency from formally 4 segments FMC (dialyses), Helios (private hospitals), Kabi(Generic & Infusions), Vamed (Projects & Digitalization) only 2 remain: Helios, Kabi, the other will be sold, and the intakes will help to restructure the financial situation under Mark Schneider the Spanish hospitals were acquired, this was a good deal: privat hospital runs well in Spain, because of their good reputation wealthy Latin Americans travel for medical treatments to Spain I focus also on: More equity than debt. Ratio is at 62% (debt/equity).
View narrative
€74.00
FV
46.3% undervalued intrinsic discount
24.16%
Revenue growth p.a.
3users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
9 months ago author updated this narrative
View Fresenius SE KGaA Community

Fresenius SE & Co. KGaA Competitors

Fresenius Medical Care

XTRA:FME

€13.7b

SYNLAB

HMSE:SYAB

€2.5b

Siemens Healthineers

XTRA:SHL

€52.1b

Carl Zeiss Meditec

XTRA:AFX

€4.5b

Price History & Performance

Summary of share price highs, lows and changes for Fresenius SE KGaA
Historical stock prices
Current Share Price€39.71
52 Week High€40.90
52 Week Low€24.62
Beta1.0
1 Month Change0.76%
3 Month Change18.57%
1 Year Change57.58%
3 Year Change19.00%
5 Year Change4.47%
Change since IPO3,417.29%

Recent News & Updates

Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Mar 31
Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Why We're Not Concerned About Fresenius SE & Co. KGaA's (ETR:FRE) Share Price

Mar 15
Why We're Not Concerned About Fresenius SE & Co. KGaA's (ETR:FRE) Share Price

Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Jan 10
Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Dec 20
Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Recent updates

Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Mar 31
Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Why We're Not Concerned About Fresenius SE & Co. KGaA's (ETR:FRE) Share Price

Mar 15
Why We're Not Concerned About Fresenius SE & Co. KGaA's (ETR:FRE) Share Price

Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Jan 10
Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Dec 20
Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Getting In Cheap On Fresenius SE & Co. KGaA (ETR:FRE) Might Be Difficult

Nov 29
Getting In Cheap On Fresenius SE & Co. KGaA (ETR:FRE) Might Be Difficult
author-image

Biopharma Innovations And Critical Growth Initiatives Propel Earnings And Margin Expansion

Nov 07 Strategic initiatives focused on productivity and organic growth are expected to enhance operational efficiency and drive margin expansion.

Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Sep 18
Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Sep 03
Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

Aug 19
Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Jul 15
We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Fresenius SE KGaA (ETR:FRE) Has Some Difficulty Using Its Capital Effectively

Jun 12
Fresenius SE KGaA (ETR:FRE) Has Some Difficulty Using Its Capital Effectively

At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

May 28
At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

May 02
With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

Shareholder Returns

FREDE HealthcareDE Market
7D-0.7%0.5%-4.4%
1Y57.6%43.9%5.4%

Return vs Industry: FRE exceeded the German Healthcare industry which returned 44.7% over the past year.

Return vs Market: FRE exceeded the German Market which returned 9% over the past year.

Price Volatility

Is FRE's price volatile compared to industry and market?
FRE volatility
FRE Average Weekly Movement3.2%
Healthcare Industry Average Movement5.3%
Market Average Movement5.6%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.8%

Stable Share Price: FRE has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: FRE's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1912176,486Michael Senwww.fresenius.com

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

Fresenius SE & Co. KGaA Fundamentals Summary

How do Fresenius SE KGaA's earnings and revenue compare to its market cap?
FRE fundamental statistics
Market cap€22.37b
Earnings (TTM)€1.04b
Revenue (TTM)€21.83b

21.5x

P/E Ratio

1.0x

P/S Ratio

Is FRE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FRE income statement (TTM)
Revenue€21.83b
Cost of Revenue€16.46b
Gross Profit€5.38b
Other Expenses€4.34b
Earnings€1.04b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 07, 2025

Earnings per share (EPS)1.85
Gross Margin24.63%
Net Profit Margin4.77%
Debt/Equity Ratio59.5%

How did FRE perform over the long term?

See historical performance and comparison

Dividends

2.5%

Current Dividend Yield

54%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/03 09:30
End of Day Share Price 2025/04/03 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Fresenius SE & Co. KGaA is covered by 47 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Martin SchneeAlphaValue
Hassan Al-WakeelBarclays
Robert BateBarclays